Abstract:Polymorphisms in the Plasmodium falciparum multidrug resistance protein 1 ( pfmdr1 ) gene and the Plasmodium falciparum chloroquine resistance transporter ( pfcrt ) gene alter the malaria parasite's susceptibility to most of the current antimalarial drugs. However, the precise mechanisms by which PfMDR1 contributes to multidrug resistance have not yet been fully elucidated, nor is it understood why polymorphisms in pfmdr1 and pfcrt that cause chloroquine resistance simultaneously increase the parasite's susceptibility to lumefantrine and mefloquine—a phenomenon known as collateral drug sensitivity. Here, we present a robust expression system for PfMDR1 in Xenopus oocytes that enables direct and high-resolution biochemical characterizations of the protein. We show that wild-type PfMDR1 transports diverse pharmacons, including lumefantrine, mefloquine, dihydroartemisinin, piperaquine, amodiaquine, methylene blue, and chloroquine (but not the antiviral drug amantadine). Field-derived mutant isoforms of PfMDR1 differ from the wild-type protein, and each other, in their capacities to transport these drugs, indicating that PfMDR1-induced changes in the distribution of drugs between the parasite's digestive vacuole (DV) and the cytosol are a key driver of both antimalarial resistance and the variability between multidrug resistance phenotypes. Of note, the PfMDR1 isoforms prevalent in chloroquine-resistant isolates exhibit reduced capacities for chloroquine, lumefantrine, and mefloquine transport. We observe the opposite relationship between chloroquine resistance-conferring mutations in PfCRT and drug transport activity. Using our established assays for characterizing PfCRT in the Xenopus oocyte system and in live parasite assays, we demonstrate that these PfCRT isoforms transport all 3 drugs, whereas wild-type PfCRT does not. We present a mechanistic model for collateral drug sensitivity in which mutant isoforms of PfMDR1 and PfCRT cause chloroquine, lumefantrine, and mefloquine to remain in the cytosol instead of sequestering within the DV. This change in drug distribution increases the access of lumefantrine and mefloquine to their primary targets (thought to be located outside of the DV), while simultaneously decreasing chloroquine's access to its target within the DV. The mechanistic insights presented here provide a basis for developing approaches that extend the useful life span of antimalarials by exploiting the opposing selection forces they exert upon PfCRT and PfMDR1.

Effects of Low Dose of Ketotifen and Chloroquine Combination on the Infrastructure of Chloroquine Resistant Strain of Plasmodium Yoelii

[Differences in Haemozoin Production and Pathogenicity Between Chloroquine-Sensitive and Chloroquine-Resistant Strains of Plasmodium Berghei].

Pathological Left‐handedness and Preserved Function Associated with a Slowly Evolving Brain Tumor

A Study of Artemether Combined with Primaquine in the Treatment of Falciparum Malaria

Mefloquine-curcumin combinations improve host mitochondrial respiration and decrease mitotoxic effects of mefloquine in Plasmodium berghei-infected mice

[A Preliminary Study on the Inhibitory Action of Target-Primaqine on the Exoerythrocytic Forms of Plasmodium Yoelii Yoelii].

Effects of co-treatment of Plasmodium berghei-infected mice with aqueous extract of Ocimum gratissimum leaves and primaquine on glucose-6-phosphate dehydrogenase activity, hematological, and antioxidant parameters

Real-Time Imaging of Antimalarial Drug Effects on Plasmodium falciparum-Infected Red Blood Cells

Co-administration of chloroquine and coenzyme Q10 improved treatment outcome during experimental cerebral malaria

Studies of Potency and Efficacy of an Optimized Artemisinin-Quinoline Hybrid against Multiple Stages of the Plasmodium Life Cycle

Advances in Pathology

Potential role of CI-679 against artemisinin-resistant Plasmodium falciparum

Efficacy and safety evaluation of a novel trioxaquine in the management of cerebral malaria in a mouse model

Anti-Malarial and Anti-Lipid Peroxidation Activities of Deferiprone-Resveratrol Hybrid in Plasmodium berghei-Infected Mice

Potency of copper(II) complexes towards drug-sensitive and -resistant Plasmodium falciparum: structure-activity relationship, ROS-generation and proteasome inhibition

Transmission-blocking activity of artesunate, chloroquine and methylene blue on gametocytes

Treatment of acute schistosomiasis mansoni with praziquantel and an antifibrotic agent in mice. Maintenance of resistance to infection

Deaggregation of mutant Plasmodium yoelii de-ubiquitinase UBP1 alters MDR1 localization to confer multidrug resistance

Therapeutic efficacy of candidate antischistosomal drugs in a murine model of schistosomiasis mansoni

Mechanistic basis for multidrug resistance and collateral drug sensitivity conferred to the malaria parasite by polymorphisms in PfMDR1 and PfCRT

Chloroquine treatment influences immunological memory through the PD-1/PD-L1 pathway during the initiation of Plasmodium chabaudi infection